|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Apexigen
gptkb:Semma_Therapeutics
|
|
gptkbp:awards
|
Best Places to Work
Top Employer in Canada
|
|
gptkbp:ceo
|
gptkb:Reshma_Kewalramani
|
|
gptkbp:clinical_trial
|
collaborative studies
Phase 3 trials
ongoing research
Phase 1 trials
Phase 2 trials
patient trials
|
|
gptkbp:collaborations
|
government agencies
academic institutions
biotech companies
|
|
gptkbp:community_involvement
|
donations
volunteering
sponsorships
|
|
gptkbp:employees
|
over 3,000
|
|
gptkbp:focus
|
gptkb:cystic_fibrosis
|
|
gptkbp:founded
|
gptkb:1989
|
|
gptkbp:funding
|
millions of dollars
|
|
gptkbp:global_presence
|
international offices
research facilities
clinical sites
|
|
gptkbp:headquarters
|
Cambridge, Massachusetts, USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vertex Pharmaceuticals (Canada) Inc.
|
|
gptkbp:instruction_set
|
multiple drug candidates
innovative therapies
new indications
|
|
gptkbp:invention
|
numerous patents
|
|
gptkbp:investment
|
annual reports
quarterly earnings
investor presentations
|
|
gptkbp:market_cap
|
over $50 billion
|
|
gptkbp:partnership
|
gptkb:Moderna
gptkb:CRISPR_Therapeutics
|
|
gptkbp:products
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:research_areas
|
autoimmune diseases
genetic diseases
|
|
gptkbp:social_responsibility
|
environmental initiatives
education initiatives
health initiatives
|
|
gptkbp:stock_symbol
|
gptkb:VRTX
|
|
gptkbp:subsidiary
|
gptkb:Vertex_Pharmaceuticals_Incorporated
|
|
gptkbp:website
|
www.vrtx.com
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|